ESPE Abstracts

Introduction: Metreleptin is a leptin replacement therapy used as an adjunct to diet to treat the metabolic complications of leptin deficiency in lipodystrophy, a rare disease characterised by loss of adipose tissue. Previously, identification of T-cell lymphomas in three metreleptin-treated patients with acquired generalised lipodystrophy (AGL) led to concerns of a potential link between metreleptin and lymphoma development.Meth...

Background: Lipodystrophy syndromes comprise a group of extremely rare and heterogeneous diseases characterized by a selective loss of adipose tissue in the absence of nutritional deprivation or catabolic state. Because of the rarity of each lipodystrophy sub-form, research in this area requires international co-operation. Therefore, in 2016, the European Consortium of Lipodystrophies (ECLip) decided to create a registry for patients affected by lipodystrophy....

Background: Lipodystrophy syndromes comprise a large group of extremely rare diseases characterized by loss or dysfunction of adipose tissue. Due to their extreme rarity and variability, research in the field of lipodystrophy is difficult for single centres warranting larger co-operations.Methods: Therefore, the European Consortium of Lipodystrophies decided to found an international registry in 2016. This registry is ba...